Tag Archives: rheumatoid arthritis; fish oil;HRT;NSAIDs; anti-inflamm

Cod Liver oil greatly reduces risky anti-inflammatory need.

This new study from the North Sea confirms what has long been common knowledge: that fish oil reduces- almost halves not just heart, mood, arrhythmia, diabetic and malignant disorders but also arthritis symptoms- and, longterm, premature mortality.

From the published studies, all that seems to matter is that reputable quality (cold-pressed) fish oil be used, and that the EPA+DHA (eicosapentanoic acid + docosahexanoic acid) dose be high enough- be it 1 or 3gms of the EPA-DHA a day. This core combination is close to 30% in average fish oil, and – within tolerance – more seems to be better.
Plant (omega 3/ 6 / 9 eg linoleic) oils should not be supplemented since these may neutralize some of the benefits of fish oil, apart from aggravating adiposity.

When combined early with appropriate vitamins, minerals, herbs eg cat’s claw, and other biologicals eg glucosamine-chondroitin and balanced parenteral human hormones, the need for corticosteroid, painkillers and synthetic anti-inflammatories seems to be much reduced- with enhanced safety.

There is no evidence from the published studies and experience that the patent ie designer non-steroidal anti-inflammatories are as good as let alone safer than cautious use of corticosteroids and glucosamine-chondroitin – which respectively slow if not reverse the course of the two major types of arthritis.

http://rheumatology.oxfordjournals.org/cgi/content/full/ken024v1 free full text
B. Galarraga, J. J. F. Belch ea, University of Dundee, Dundee, UK.
Rheumatology, March 24, 2008; (2008) ken024v1. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis

Dose-dependant side-effects limit the use of NSAIDs in the management of RA. T Double-blind placebo-controlled randomized study of 9 months’ duration. 97 patients with RA were randomized to take either 10 g of cod liver oil containing 2.2 g of n-3 EFAs or placebo capsules. At 12 weeks, patients were instructed to gradually reduce and if possible, stop their NSAID intake. Relative reduction of daily NSAID requirement after 9 months was the primary outcome measure.
Results. 58patients (60%) completed the study. Out of 49 patients 19 (39%) in the cod liver oil group and out of 48 patients 5 (10%) in the placebo group were able to reduce their daily NSAID requirement by >30% (P = 0.002, chi-squared test). No differences between the groups were observed in the clinical parameters of RA disease activity or in the side-effects observed. Conclusions. This study suggests that cod liver oil supplements containing n-3 fatty acids can be used as NSAID-sparing agents in RA patients.